Mostrar el registro sencillo del ítem

dc.contributor.authorGarcía-Caballero, Melissa
dc.contributor.authorCañedo, Librada
dc.contributor.authorFernández-Medarde, Antonio
dc.contributor.authorRodríguez-Quesada, Ana María 
dc.contributor.authorMedina-Torres, Miguel Ángel 
dc.date.accessioned2014-09-16T09:50:58Z
dc.date.available2014-09-16T09:50:58Z
dc.date.created2014-09-11
dc.date.issued2014-09-16
dc.identifier.urihttp://hdl.handle.net/10630/8040
dc.description.abstractIn the course of a screening program for the inhibitors of angiogenesis from marine sources, AD0157, a pyrrolidinedione fungal metabolite, was selected for its angiosupressive properties. AD0157 inhibited the growth of endothelial and tumor cells in culture in the micromolar range. Our results show that subtoxic doses of this compound inhibit certain functions of endothelial cells, namely, differentiation, migration and proteolytic capability. Inhibition of the mentioned essential steps of in vitro angiogenesis is in agreement with the observed antiangiogenic activity, substantiated by using two in vivo angiogenesis models, the chorioallantoic membrane and the zebrafish embryo neovascularization assays, and by the ex vivo mouse aortic ring assay. Our data indicate that AD0157 induces apoptosis in endothelial cells through chromatin condensation, DNA fragmentation, increases in the subG1 peak and caspase activation. The data shown here altogether indicate for the first time that AD0157 displays antiangiogenic effects, both in vitro and in vivo, that are exerted partly by targeting the Akt signaling pathway in activated endothelial cells. The fact that these effects are carried out at lower concentrations than those required for other inhibitors of angiogenesis makes AD0157 a new promising drug candidate for further evaluation in the treatment of cancer and other angiogenesis-related pathologies. [Our experimental work is supported by grant P12-CTS-1507 (Andalusian Government and FEDER) and funds from group BIO-267 (Andalusian Government). The "CIBER de Enfermedades Raras" is an initiative from the ISCIII (Spain). This communication has the support of a travel grant "Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech"].es_ES
dc.description.sponsorshipUniversidad de Málaga. Campus de Excelencia Internacional Andalucía Teches_ES
dc.language.isoenges_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectNeovascularizaciónes_ES
dc.subject.otherAngiogenesises_ES
dc.subject.otherAkt signalinges_ES
dc.subject.otherApoptosises_ES
dc.subject.otherNatural productses_ES
dc.titleAD0157, a pyrrolidinedione fungal metabolite, inhibits angiogenesis by targeting the Akt signaling pathwayes_ES
dc.typeinfo:eu-repo/semantics/conferenceObjectes_ES
dc.centroFacultad de Cienciases_ES
dc.relation.eventtitleXXXVII Congreso SEBBMes_ES
dc.relation.eventplaceGranada, Españaes_ES
dc.relation.eventdateDel 9 al 12 de Septiembre de 2014es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem